Antigens of the Gerbich blood group system are expressed on glycophorin C (GPC) and glycophorin D (GPD), minor sialoglycoproteins of human erythrocytes. GPC and GPD help maintain erythrocyte shape of and contributes to the stability of its membrane. There are six high-prevalence Gerbich antigens: Ge2, Ge3, Ge4, GEPL (GE10), GEAT (GE11), GETI (GE12) and five low-prevalence Gerbich antigens: Wb (GE5), Ls a (GE6), An a (GE7), Dh a (GE8), GEIS (GE9). Some Gerbich antigens (Ge4, Wb, Dh a , GEAT) are expressed only on GPC, two (Ge2, An a ) are expressed only on GPD, while others (Ge3, Ls a are minor sialoglycoproteins of human RBCs [1] [2] [3] . GPC is primarily expressed early during normal and leukemic erythroid differentiation [4, 5] . However, GPC, unlike GPA and GPB, is not restricted to the erythroid lineage and is also found on B and T lymphocytes, monocytes, and myeloid precursors [6] . Moreover, GPC mRNA was detected in many non-hematopoietic tissues, including the thymus, stomach, breast, and fetal and adult liver [7] .
GPC and GPD are type I transmembrane proteins that consist of three domains: an extracellular N-terminal domain, a transmembrane domain, and a cytoplasmic C-terminal domain (Fig 1) . GPC and GPD are encoded by the same gene (GYPC) and arise as the result of leaky translation from two initiation codons; thus, GPD is a truncated version of GPC [8] . The polypeptide chain of GPC is composed of 128 a.a. residues with one N-glycan (at Asn8) and approximately 12 O-glycans (Fig 1) [9, 10] . GPD starts from what is Met22 in GPC; thus, it consists of 107 a.a. residues and lacks the N-glycan.
GPC and GPD play important roles in maintaining RBC shape and mechanically stabilizing the RBC membrane [11, 12] . They form complexes with proteins 4.1 and p55, which provide a membrane mooring system for the spectrin-actin network [13, 14] (Fig 2) . C-terminal a.a. residues 86-88 (RHK) of GPC interact with protein 4.1, while p55 engages residues 126-128 (YFI) [15, 16] . The similarity of the GPC cytoplasmic tail sequences in many evolutionarily distant mammals underscores its importance as a plasma membrane link to the cytoskeleton (Fig 3) .
The absence of GPC and GPD or protein 4.1 causes hereditary elliptocytosis [17] . Protein 4.1 deficiency causes a 70-90% decrease of GPC and GPD content in the RBC membrane [18] . Conversely, GPC/GPDdeficient RBCs show a 25% reduction of protein 4.1 [19, 20] . Depression of the Kell blood group antigens in the Ge:-2,-3 (Gerbich) rare type was also described, initially reported in a K+ woman and her brother, with approximately half the number of K antigen sites compared to K + k+, Ge:2,3 control RBCs [21] . Daniels described various degrees of weakening of high-frequency Kell antigens, especially K11, in 9 out of 11 Ge:-2,-3 subjects [22] . Another group observed that K + k+, Ge:-2,-3 RBCs showed a K antigen density three times lower than K + k-, Ge:2,3 RBCs [23] . A weakened expression of the k antigen in Ge:-2,-3 people was recently confirmed with the use of a monoclonal anti-k [24] . However, this k antigen depression appeared to be moderate (about −25%) and not easily detected with standard typing procedures. The authors also unexpectedly found a seemingly higher expression of the k antigen in Ge:-2,3 (Yus) RBCs when compared to standard RBCs, though this is still not explained. Thus, these effects may suggest conformational changes of Kell epitopes due to perturbation of macromolecular protein 4.1 complex with transmembrane proteins including GPC (Gerbich) and Kell [13] .
Glycophorins C and D carry the Gerbich blood group antigens
The GYPC gene (13.5 kbp) contains four exons and is on chromosome 2q14-q21 [25] . The high degree of homology between exons 2 and 3 may lead to unequal crossing over and loss of exon 2 or 3, causing
Amino acid sequence and domain structure of GPC and its glycan structure and attachment sites [9, 10] . The external (aa 1-57), transmembrane (aa 58-81) and cytoplasmic (aa 82-128) domains are marked in green, yellow, and blue, respectively. [15] and (YFI) for p55 [16] are indicated.
rare "Gerbich-negative" phenotypes, in which RBCs lack one or several of the high-prevalence antigens Ge2, Ge3 and Ge4, which are encoded by exons 2, 3 and 1, respectively [26] [27] [28] [29] . The absence of exon 2 results in the rare Yus ("Yussef") phenotype (Ge:-2,3,4) [10, 30] , especially encountered in the Mediterranean and Middle East area, while the absence of exon 3 results in the rare Gerbich phenotype (Ge:-2,-3,4) which is almost exclusively found among Melanesians [10, 30] . Of note, Ge1, initially claimed to be lacking a high-prevalence Gerbich antigen in Melanesians, was later declared obsolete; this is the reason why Ge2 is now the first antigen within the Gerbich blood group system.
The emergence of Gerbich variants probably resulted from selective pressure exerted by P. falciparum, because deletion alleles frequently occurred in malaria-endemic areas, including the Middle East and Papua New Guinea. RBCs with a rare Gerbich and Yus phenotype contain shortened deletion variants of GPC/GPD molecules, which migrate in SDS-PAGE as broad diffuse bands due to differences in glycosylation [30, 31] . Interestingly, Gourri et al. described 4 different alleles involved in the Yus phenotype, characterized by deletions of exon 2 and adjacent introns, and 3 different alleles responsible for the Gerbich type, with deletions of exon 3 and adjacent introns [32] . They showed that a 3600 base pair GYPC region, encompassing exon 2 and its flanking region, shares a high degree of sequence similarity with a region flanking exon 3, probably representing an evolutionary duplication event. After determining the precise breakpoints of all the deletion alleles, they developed a set of 15 diagnostic PCR-SSP assays for detecting all the different Yus and Gerbich alleles reported to date.
The null phenotype, called Leach or Gerbich null (Ge:-2,-3,-4), is caused by deletion of exons 3 and 4 (Leach type I) [10] or a nucleotide change in exon 3 (Leach type II) resulting in a frame-shift and a premature stop codon [33] . The Leach phenotype is considered exceptional, with only a very few cases reported in people of Western European ancestry. This exceedingly rare phenotype is totally devoid of both GPC and GPD and shows elliptocytic RBCs along with a mild anemia.
There are six known high-prevalence Gerbich antigens: Ge2, Ge3, Ge4, GEPL (GE10), GEAT (GE11), GETI (GE12); and five low-prevalence antigens: Ls a (GE6) [34] [35] [36] , An a (GE7) [37] , Dh a (GE8) [38] , Wb (GE5) [39] , GEIS (GE9) [40] (Table 1) . Some Gerbich antigens (Ge4, Wb, Dh a , GEAT) are expressed only on GPC, two (Ge2, An a ) are expressed only on GPD, and Ge3, Ls a , GEIS, GEPL, and GETI are expressed on both GPC and GPD [41, 42] . Ge2 is located only at the N-terminus of GPD (so it is not expressed on GPC), while Ge4 is located only on the N-terminus of GPC (which is missing in GPD). Ge3 is expressed on both GPC and GPD as an internal epitope located close to the lipid bilayer (a.a. [42] [43] [44] [45] [46] [47] [48] [49] [50] . The other six high-frequency antigens result from single nucleotide changes in GYPC [41, 42] .
Antibodies to Gerbich blood group antigens
Antibodies to Gerbich blood group antigens usually result from pregnancy or transfusion, but may also occur naturally [42] . In several cases, Gerbich antibodies were clinically significant [33, [41] [42] [43] [44] . Alloimmunization to Gerbich antigens leads to different outcomes: individuals with the rare Leach phenotype may form either anti-Ge2, anti-Ge3, or anti-Ge4, those with the rare Gerbich phenotype may develop either anti-Ge2 or anti-Ge3, while those with the rare Yus phenotype exclusively make anti-Ge2 [32, 45, 46] ; this might be due to the higher immunogenicity of the Ge2 antigen as compared to Ge3 and Ge4.
Alloantibodies to Gerbich blood group antigens may cause hemolytic transfusion reactions (HTR). These are usually mild, and the systematic use of rare phenocompatible RBC units in Yus, Gerbich, or Leach patients is a matter of debate among immunohematologists and blood banking specialists. Of note, one case of an acute HTR was described in a patient with anti-Ge3, who was repeatedly transfused with standard RBCs [43] . Recently, another case of an acute HTR was reported in an individual with antibodies against Wb, a low-frequency antigen (Table 1 ) [47] . The investigation of antibodies directed to a high-prevalence Gerbich antigen is one of two top indications (along with anti-Yt a ) for using the "monocyte monolayer assay" (MMA), an in vitro test performed to predict the clinical significance of RBC alloantibodies [48] . Out of 29 examples of Gerbich alloantibodies, 16 (59%) showed a positive MMA test (N5% of reactivity), including 8 samples with strongly positive reactivity of N20% [49] . Some countries, as is the case in France, strive to systematically provide rare Ge:-2,3 or Ge:-2,-3 RBC units in alloimmunized patients with these phenotypes. In rare cases, alloantibodies to Gerbich blood group antigens may cause moderate to severe hemolytic disease of the fetus and newborn (HDFN) and late-onset mild neonatal anemia [50, 51] . Children born with HDFN caused by anti-Ge3 usually present with mildly elevated reticulocyte counts and bilirubin levels; however, 
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Fig 3.
Comparison of mammalian GPC amino acid sequences. The binding sites on GPC for protein 4.1 (RHK) [15] and p55 (YFI) [16] are marked with boxes. they sometimes have severe anemia. The proposed mechanism underlying Gerbich-related HDFN includes macrophage-dependent cell destruction and inhibition of early erythroid progenitor cell proliferation. In addition, autoantibodies of anti-Ge2 or anti-Ge3 specificity can cause severe autoimmune hemolytic anemia (AIHA) [52] [53] [54] [55] . Several monoclonal antibodies recognizing different epitopes on GPC/GPD were produced [56, 57] . Most recognize N-terminal epitopes of GPC that include Met1, and thus resemble anti-Ge4, but some recognize internal epitopes on GPC/GPD, including a.a. 13-20, 36-39, 42-50 (resembling anti-Ge3) [58] [59] [60] [61] and 105-110 [7] . Most anti-Ge4 monoclonal antibodies recognize sialic acid-containing glycopeptide epitopes [62] on GPC/GPD. The fine specificities of these antibodies were characterized using recombinant forms of GPC [63] [64] [65] .
GPC and GPD as receptors for Plasmodium merozoites
Protozoa belonging to the genus Plasmodium cause malaria. Humans are susceptible to five Plasmodium species: P. vivax, P. ovale, P. malariae, P. knowlesi and P. falciparum. P. vivax is the most widespread malaria parasite, while P. falciparum generates the highest death toll [66] .
RBC invasion by blood-stage malaria parasites is complicated, involving host-specific interactions between merozoite ligands and host RBC receptors. Several RBC membrane proteins are involved in invasion by Plasmodium merozoites [67] [68] [69] [70] . These belong to two families: Duffy binding-like (DBL) and reticulocyte binding-like (RBL) [71] . The P. falciparum DBL family includes several erythrocyte binding-ligands (EBL), which recognize different RBC receptors (Table 2) thereby enabling merozoites to invade RBCs through alternative pathways. Four P. falciparum erythrocyte binding ligands have been identified: erythrocyte binding antigen-175 (EBA-175), EBA-140, EBA-181 and EBL-1 [72] . These all contain several conserved regions, such as Region II, which is involved in binding to RBC receptors. EBA-175 and its paralogue, EBA-140 [73] [74] [75] , recognize sialic acid residues in clusters of O-linked glycans attached to GPA (the most abundant human erythrocyte glycophorin) and GPC, respectively [76] . EBA-140 binding also requires sialic acid residues linked to the N-glycan, which is present in GPC, but not in GPD [76] [77] [78] [79] [80] [81] [82] .
Disruption of the EBA-140-encoding gene of P. falciparum abrogates the ability of the Pf ΔEBA-140 strain to bind GPC on RBCs [80] . Studies using recombinant forms of the EBA-140 binding region (Region II) expressed in COS7 or CHO-K1 cells suggested that polymorphisms at specific amino acid positions determine receptor binding specificity [82, 83] . However, these results were refuted by Maier et al., who showed that polymorphisms in Region II of EBA-140 antigen from different Plasmodium strains affect only the binding level, but not its GPC specificity [84] . EBA-140 does not bind Gerbich-type GPC [80] [81] [82] [83] [84] [85] , suggesting that the region encompassing a.a. residues 36-63, which is missing in GPC-Gerbich, comprises at least part of the EBA-140 binding site. However, other data show that a.a. residues 13-22 of GPC are important for binding [79] .
Many aspects of the EBA-140-GPC binding interactions remain to be elucidated. While it is generally accepted that sialylated oligosaccharide chains on GPC participate in binding EBA-140, the role of individual O-glycans was not evaluated. On the other hand, the GPC N-glycan is clearly essential for binding [85] . Therefore, the O-glycans and N-glycan on GPC seem to comprise the EBA-140 binding site. In addition, although sialylated glycans on GPC garner the most attention, the GPC protein backbone is also involved in binding to EBA-140 [81, 86] . The essential role of the N-terminal region of GPC is underscored by the observation that the rare Gerbich phenotype (Ge:-2,-3,4) is common in Papua New Guinea, where P. falciparum is endemic [80, 87] .
Homologs of EBL merozoite ligands, including EBA-140, were identified in P. reichenowi, the chimpanzee counterpart of P. falciparum [88] [89] [90] . Since GPC is only expressed in humans [91] , it was suggested that GPD is a chimpanzee RBC receptor for P. reichenowi EBA-140 [92, 93] Interesting data also come from studies using the P. berghei rodent malaria model. Recently, a novel approach, involving mouse embryonic stem cells with single gene deletions and erythropoietic differentiation, was used to identify RBC receptors for P. berghei merozoites [94] . Deletion of GYPC, leading to the absence of GPC on mouse stem cell-derived RBCs, caused a sharp drop in invasion rate by P. berghei (by 66% at 6 hours and 86% at 24 hours post-infection). The magnitude of these changes suggests that P. berghei is much more dependent on GPC on mouse RBCs than P. falciparum on human RBCs [94] . The P. berghei genome contains one EBL family protein with homology to P. falciparum EBA-140, PBANKA-1332700, which is the obvious candidate ligand for mouse GPC.
The fatal course of P. falciparum malaria correlates with expression of the parasite genes encoding variant surface antigens (var) [95, 96] . Once the parasite invades RBCs, it releases Var antigens, including erythrocyte membrane protein 1 (EMP1), STEVOR, and RIFIN, which travel to the RBC plasma membrane and eventually emerge on the RBC surface. Dozens of gene variants encoding each protein are present in a single P. falciparum genome, the expression of which may be switched on and off with each intraerythrocytic proliferation cycle. This generates tremendous antigenic variation, which enables the parasite to escape host immunity. In addition, var-encoded proteins bind host proteins on uninfected RBCs and endothelium, leading to sequestration of infected RBCs, thereby saving them from splenic destruction [96] . The clumps of uninfected RBCs bound by infected RBCs form rosettes, which shields infected RBCs from the environment, possibly providing another mechanism of immune evasion for the parasite [97] . However, the role of the rosetting phenomenon in vivo remains unknown. Indeed, rosetting may be largely an in vitro phenomenon. The interactions involved in P. falciparum rosette formation correspond to PfEMP1 ligand and its receptors, such as complement receptor 1 [98] , blood group antigens (A and B) [99] , heparan sulfate [100] and trombospondin [101] . In addition, rosetting by the P. falciparum STEVOR protein is mediated by RBC membrane-bound GPC [102] . Thus, soluble GPC prevents rosetting and binding of STEVOR to RBCs. Moreover, knock-down of GPC dramatically reduces the RBC's susceptibility to rosette formation.
While most malaria-induced rosetting data come from P. falciparum experiments, the phenomenon occurs in all cases of human malaria; in the case of P. vivax, rosetting may also involve GPC. Interestingly, rosettes formed by P. vivax favor mature RBCs (normocytes) over reticulocytes [103] , although P. vivax merozoites exclusively invade reticulocytes, indicating that this process is unlikely to facilitate merozoite invasion. In addition, an antibody recognizing the N-terminal region of GPC significantly inhibited P. vivax rosette formation. Finally, knock-down of GPC reduced the involvement of mature RBCs in rosette formation. Thus, GPC may also play a role in the life cycle of P. vivax.
Conclusions
The Gerbich blood group system consists of several high-and lowfrequency antigens that are expressed on GPC and GPD. These minor glycophorins on human RBCs play important roles as anchors for the cytoskeleton, thereby contributing to RBC mechanical stability. In recent years, considerable progress was made in demonstrating that GPC/GPD are receptors for P. falciparum merozoites, and that the genetic diversity resulting from mutations in the GYPC gene plays an important role in host resistance to P. falciparum. In particular, a growing body of evidence shows that most mutations causing a loss of Gerbich high-prevalence antigens may reduce the RBC's susceptibility to P. falciparum merozoite invasion. Thus, the Gerbich blood group system emerges as a major player in the Plasmodium interaction with human RBCs, giving some individuals in malaria-endemic regions partial protection against malaria.
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